ET140203 T Cells for Liver Cancer

Recruiting in Palo Alto (17 mi)

+4 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Eureka Therapeutics Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?

Open-label, dose escalation, multi-center, Phase I / II study to assess the safety of an autologous T-cell product (ET140203) in adult subjects with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive advanced hepatocellular carcinoma (HCC).

Research Team

Pei Wang, PhD

Principal Investigator

Eureka Therapeutics Inc.

Eligibility Criteria

Adults with advanced liver cancer (Hepatocellular Carcinoma) who have high levels of a protein called AFP, carry the HLA-A2 gene, and whose cancer is not removable by surgery. Participants must have tried at least two other treatments without success, be relatively healthy otherwise, and expected to live at least 4 more months.

Inclusion Criteria

My liver functions well despite my illness.

Platelet count greater than or equal to 75,000/mm^3

Absolute neutrophil count greater than or equal to 1,500/mm^3

See 7 more

Exclusion Criteria

I have a serious heart condition.

I have a significant brain or nerve condition.

I do not have any serious ongoing illnesses or infections.

See 5 more

Treatment Details

Interventions

ET140203 autologous T cell product (CAR T-cell Therapy)

Trial OverviewThe trial is testing ET140203 autologous T cell product in adults with liver cancer. It's an early-phase study to see if this treatment is safe. Patients will receive their own modified T cells designed to target their tumor.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: ET140203 TCellsExperimental Treatment1 Intervention

ET140203 T Cells